logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn forms partnership with Chinese medical services provider to fight deadly coronavirus

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biopharma has signed a nonbinding letter of intent with Chinese medical services provider Longen China Group to develop and license its drug leronlimab as a treatment for coronavirus.

Pourhassan says its important the companies will work together to find potential uses for leronlimab in fighting the coronavirus, which has killed more than 1,000 people.

Quick facts: CytoDyn Inc.

Price: 1.095 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $471.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn looks to schedule emergency Type C meeting with FDA...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company will request an emergency Type C meeting with the FDA to enroll 50 patients with solid tumor cancer conditions.  Pourhassan says the Vancouver, Washington-based company was...

3 weeks, 1 day ago

2 min read